BETRF on OTC

BetterLife Pharma Inc.

Price unavailable

Last updated Oct 16, 2026.

Overview

-3.6MNet income, fiscal 20252

Compare with another stock.

  • TickerBETRF on OTC
  • IndustryPharmaceutical Preparations
  • HeadquartersA1
  • Incorporated inBritish Columbia, Canada3
  • Business address1275 West 6Th Avenue, Vancouver, A1 V6H 1A63
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income42-$5.0M in 2025+377% since 2018
-$10.0M-$7.5M-$5.0M-$2.5M02018: -$1.0M-$1.0M20182023: -$9.5M-$9.5M2023+802%2024: -$3.2M-$3.2M2024−66%2025: -$5.0M-$5.0M2025+54%
Net income456782-$3.6M in 2025+2889% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$121.2K-$121.2K20182019: -$9.3M-$9.3M2019+7537%2020: -$19.6M-$19.6M2020+112%2021: -$36.4M-$36.4M2021+86%2022: -$12.2M-$12.2M2022−67%2023: -$9.4M-$9.4M2023−23%2024: -$2.9M-$2.9M2024−69%2025: -$3.6M-$3.6M2025+25%

Every line of the income statement in the latest annual report, as filed.9

Period ending2026-01-312025-01-312024-01-31
Consulting fees170.0K CAD1.1M CAD399.8K CAD
Foreign exchange (gain) loss-200.9K CAD275.2K CAD30.4K CAD
General and administrative203.9K CAD260.5K CAD271.7K CAD
Professional fees265.5K CAD499.3K CAD526.5K CAD
Research and development85.7K CAD424.3K CAD570.9K CAD
Wages, salaries and employment expenses1.1M CAD2.4M CAD1.4M CAD
Total expenses1.6M CAD5.0M CAD3.2M CAD
Loss from operations-1.6M CAD-5.0M CAD-3.2M CAD
Accretion expense (Notes 5 and 6)-77.5K CAD-154.4K CAD-5.4K CAD
Changes in fair values of warrant liabilities (Notes 9(a) and 9(b))197.9K CAD-33.4K CAD-137.8K CAD
Financial guarantee recovery (expense) (Note 16(c))-30.4K CAD758.8K CAD-34.0K CAD
Gain on extinguishment/forgiveness of debts (Note 14)150.0K CAD110.2K CAD469.1K CAD
Gain on loan extinguishment (Note 6)9.9K CAD0 CAD0 CAD
Interest expense-154.4K CAD-165.1K CAD-45.5K CAD
Other-679 CAD9 CAD-945 CAD
Penalties recovery (expense)0 CAD305.4K CAD-33.7K CAD
Settlements and legal provisions, net (Notes 14, 16(a) and 16(d))0 CAD556.6K CAD130.0K CAD
Total other income94.8K CAD1.4M CAD341.7K CAD
Net loss for the year-1.5M CAD-3.6M CAD-2.9M CAD
Foreign currency translation adjustment of foreign operations5.1K CAD-30.6K CAD-4.9K CAD
Comprehensive loss for the year-1.5M CAD-3.7M CAD-2.9M CAD
Company's shareholders-1.5M CAD-3.5M CAD-2.9M CAD
Non-controlling interests (Note 12)-17.4K CAD-101.6K CAD-9.5K CAD
Net loss-1.5M CAD-3.6M CAD-2.9M CAD
Company's shareholders-1.5M CAD-3.6M CAD-3.0M CAD
Non-controlling interests (Note 12)-17.2K CAD-101.6K CAD53.6K CAD
Comprehensive loss-1.5M CAD-3.7M CAD-2.9M CAD
Net loss per share, basic and diluted-0.01 CAD-0.03 CAD-0.03 CAD
Weighted average shares outstanding, basic and diluted145.9M shares123.9M shares109.3M shares

Compare BetterLife Pharma Inc. with another company

Former names

  • Pivot Pharmaceuticals Inc.Apr 17, 2015 to Dec 3, 20193
  • Neurokine Pharmaceuticals Inc.Aug 7, 2009 to Mar 26, 20153

Recent filings

  1. Sep 30, 20266-K
  2. Sep 22, 2026SCHEDULE 13G
  3. Sep 15, 20266-K
  4. Sep 11, 20266-K
  5. Aug 24, 20266-K
  6. Aug 5, 20266-K
  7. Jun 26, 20266-K
  8. Jun 25, 20266-K
  9. Jun 1, 202620-F
  10. Apr 13, 20266-K
  11. Sep 29, 20256-K
  12. Jul 28, 20256-K
  13. Jun 27, 20256-K
  14. Jun 23, 20256-K
  15. Jun 2, 202520-F

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10